|
1
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Clarke RB: p27KIP1
phosphorylation by PKB/Akt leads to poor breast cancer prognosis.
Breast Cancer Res. 5:162–163. 2003. View
Article : Google Scholar :
|
|
4
|
Chang F, Lee JT, Navolanic PM, Steelman
LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA:
Involvement of PI3K/Akt pathway in cell cycle progression,
apoptosis, and neoplastic transformation: A target for cancer
chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo
P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt
promotes cell survival by phosphorylating and inhibiting a Forkhead
transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pratheeshkumar P, Budhraja A, Son YO, Wang
X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, et al:
Quercetin inhibits angiogenesis mediated human prostate tumor
growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling
pathways. PLoS One. 7:e475162012. View Article : Google Scholar
|
|
7
|
Li W, Tan D, Zhang Z, Liang JJ and Brown
RE: Activation of Akt-mTOR-p70S6K pathway in angiogenesis in
hepatocellular carcinoma. Oncol Rep. 20:713–719. 2008.PubMed/NCBI
|
|
8
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schwartsmann G, Di Leone LP, Dal Pizzol F
and Roesler R: MAPK pathway activation in colorectal cancer: A
therapeutic opportunity for GRP receptor antagonists. Lancet Oncol.
6:444–445. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fang JY and Richardson BC: The MAPK
signalling pathways and colorectal cancer. Lancet Oncol. 6:322–327.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Quartuccio SM, Lantvit DD, Bosland MC and
Burdette JE: Conditional inactivation of p53 in mouse ovarian
surface epithelium does not alter MIS driven Smad2-dominant
negative epithelium-lined inclusion cysts or teratomas. PLoS One.
8:e650672013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Van Cutsem E and Costa F: Progress in the
adjuvant treatment of colon cancer: Has it influenced clinical
practice? JAMA. 294:2758–2760. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Longley DB, Allen WL and Johnston PG: Drug
resistance, predictive markers and pharmacogenomics in colorectal
cancer. Biochim Biophys Acta. 1766:184–196. 2006.PubMed/NCBI
|
|
14
|
Lippman SM: The dilemma and promise of
cancer chemoprevention. Nat Clin Pract Oncol. 3:5232006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma X and Wang Z: Anticancer drug discovery
in the future: An evolutionary perspective. Drug Discov Today.
14:1136–1142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gordaliza M: Natural products as leads to
anticancer drugs. Clin Transl Oncol. 9:767–776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Newman DJ, Cragg GM and Snader KM: The
influence of natural products upon drug discovery. Nat Prod Rep.
17:215–234. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin J, Wei L, Shen A, Cai Q, Xu W, Li H,
Zhan Y, Hong Z and Peng J: Hedyotis diffusa Willd extract
suppresses Sonic hedgehog signaling leading to the inhibition of
colorectal cancer angiogenesis. Int J Oncol. 42:651–656. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cai Q, Lin J, Wei L, Zhang L, Wang L, Zhan
Y, Zeng J, Xu W, Shen A, Hong Z, et al: Hedyotis diffusa Willd
inhibits colorectal cancer growth in vivo via inhibition of STAT3
signaling pathway. Int J Mol Sci. 13:6117–6128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin J, Chen Y, Wei L, Chen X, Xu W, Hong
Z, Sferra TJ and Peng J: Hedyotis Diffusa Willd extract induces
apoptosis via activation of the mitochondrion-dependent pathway in
human colon carcinoma cells. Int J Oncol. 37:1331–1338.
2010.PubMed/NCBI
|
|
21
|
Lin J, Chen Y, Cai Q, Wei L, Zhan Y, Shen
A, Sferra TJ and Peng J: Scutellaria Barbata D Don inhibits
colorectal cancer growth via suppression of multiple signaling
pathways. Integr Cancer Ther. 13:240–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wei L, Lin J, Wu G, Xu W, Li H, Hong Z and
Peng J: Scutellaria barbata D. Don induces G1/S arrest via
modulation of p53 and Akt pathways in human colon carcinoma cells.
Oncol Rep. 29:1623–1628. 2013.PubMed/NCBI
|
|
23
|
Wei L, Lin J, Xu W, Cai Q, Shen A, Hong Z
and Peng J: Scutellaria barbata D. Don inhibits tumor angiogenesis
via suppression of Hedgehog pathway in a mouse model of colorectal
cancer. Int J Mol Sci. 13:9419–9430. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen L, Liu L, Ye L, Shen A, Chen Y,
Sferra TJ and Peng J: Patrinia scabiosaefolia inhibits colorectal
cancer growth through suppression of tumor angiogenesis. Oncol Rep.
30:1439–1443. 2013.PubMed/NCBI
|
|
25
|
Liu L, Shen A, Chen Y, Wei L, Lin J,
Sferra TJ, Hong Z and Peng J: Patrinia scabiosaefolia induces
mitochondrial-dependent apoptosis in a mouse model of colorectal
cancer. Oncol Rep. 30:897–903. 2013.PubMed/NCBI
|
|
26
|
Peng J, Chen Y, Lin J, Zhuang Q, Xu W,
Hong Z and Sferra TJ: Patrinia scabiosaefolia extract suppresses
proliferation and promotes apoptosis by inhibiting the STAT3
pathway in human multiple myeloma cells. Mol Med Rep. 4:313–318.
2011.PubMed/NCBI
|
|
27
|
Liu J: Oleanolic acid and ursolic acid:
Research perspectives. J Ethnopharmacol. 100:92–94. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang X, Bai H, Zhang X, Liu J, Cao P, Liao
N, Zhang W, Wang Z and Hai C: Inhibitory effect of oleanolic acid
on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest
and mitochondrial-dependent apoptosis. Carcinogenesis.
34:1323–1330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lúcio KA, Rocha GG, Monção-Ribeiro LC,
Fernandes J, Takiya CM and Gattass CR: Oleanolic acid initiates
apoptosis in non-small cell lung cancer cell lines and reduces
metastasis of a B16F10 melanoma model in vivo. PLoS One.
6:e285962011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen Y, Robles AI, Martinez LA, Liu F,
Gimenez-Conti IB and Conti CJ: Expression of G1 cyclins,
cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in
androgen-induced prostate proliferation in castrated rats. Cell
Growth Differ. 7:1571–1578. 1996.PubMed/NCBI
|
|
33
|
Graña X and Reddy EP: Cell cycle control
in mammalian cells: Role of cyclins, cyclin dependent kinases
(CDKs), growth suppressor genes and cyclin-dependent kinase
inhibitors (CKIs). Oncogene. 11:211–219. 1995.PubMed/NCBI
|
|
34
|
Chung DC, Brown SB, Graeme-Cook F, Seto M,
Warshaw AL, Jensen RT and Arnold A: Overexpression of cyclin D1
occurs frequently in human pancreatic endocrine tumors. J Clin
Endocrinol Metab. 85:4373–4378. 2000.PubMed/NCBI
|
|
35
|
Keum JS, Kong G, Yang SC, Shin DH, Park
SS, Lee JH and Lee JD: Cyclin D1 overexpression is an indicator of
poor prognosis in resectable non-small cell lung cancer. Br J
Cancer. 81:127–132. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Harper JW, Adami GR, Wei N, Keyomarsi K
and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent
inhibitor of G1 cyclin-dependent kinases. Cell. 75:805–816. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Adams JM and Cory S: Bcl-2-regulated
apoptosis: Mechanism and therapeutic potential. Curr Opin Immunol.
19:488–496. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Peng J, Ding J, Tan C, Baggenstoss B,
Zhang Z, Lapolla SM and Lin J: Oligomerization of membrane-bound
Bcl-2 is involved in its pore formation induced by tBid. Apoptosis.
14:1145–1153. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Peng J, Tan C, Roberts GJ, Nikolaeva O,
Zhang Z, Lapolla SM, Primorac S, Andrews DW and Lin J: tBid elicits
a conformational alteration in membrane-bound Bcl-2 such that it
inhibits Bax pore formation. J Biol Chem. 281:35802–35811. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yip KW and Reed JC: Bcl-2 family proteins
and cancer. Oncogene. 27:6398–6406. 2008. View Article : Google Scholar : PubMed/NCBI
|
